Yasuhiro Funahashi,Tadashi Kadowaki,Junji Matsui,Jason S. Simon,Lucy Xu
申请号：
US14122339
公开号：
US09945862B2
申请日:
2012.05.31
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Biomarkers are provided that are predictive of a subjects responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
